Novel fat accumulation inhibitory peptide and pharmaceutical composition for preventing or treating obesity containing the same

Patent metadata

Field	Value
Publication number	US-2017326201-A1
Application number	US-201715666506-A
Country	US
Kind code	A1
Filing date	Aug 1, 2017
Priority date	Jul 24, 2014
Publication date	Nov 16, 2017
Grant date	—

Abstract

The disclosure relates to a fat accumulation inhibitory peptide which essentially comprises an amino acid sequence represented by SEQ ID NO: 1, a pharmaceutical composition for preventing or treating obesity, which contains the peptide, and a health functional food for preventing or alleviating obesity, which contains the peptide. The fat accumulation inhibitory peptide according to the present invention has the function of inhibiting the differentiation of mesenchymal stem cells into adipocytes to thereby inhibit the accumulation of adipose tissue. Thus, the peptide according to the present invention is highly useful for the prevention or treatment of obesity.

First claim

1 . A method for inhibiting fat accumulation, comprising administering a fat accumulation inhibitory peptide which essentially comprises the amino acid sequence represented by SEQ ID NO: 1 to a subject in need of fat accumulation inhibition.

2 . The method of claim 1 , wherein the fat accumulation inhibitory peptide consists of the amino acid sequence represented by SEQ ID NO: 2.

3 . The method of claim 1 , wherein the peptide acts to inhibit the differentiation of mesenchymal stem cells into adipocytes.

4 . A method for preventing or treating obesity, comprising administering a pharmaceutical composition which comprises the amino acid sequence represented by SEQ ID NO: 1 to a subject in need of reducing obesity.

5 . The method of claim 4 , wherein the obesity is obesity caused by estrogen deficiency.

6 . The method of claim 4 , wherein the pharmaceutical composition is administered by oral administration, injection administration, or local transplantation in the form of a gelling agent.

7 . The method of claim 6 , wherein the gelling agent comprises a synthetic polymer or a natural polymer.

8 . The method of claim 7 , wherein the synthetic polymer is any one selected from the group consisting of polylacticglycolic acid, poloxamer, and propylene glycol.

9 . The method of claim 7 , wherein the natural polymer is any one selected from the group consisting of collagen, alginic acid, propylene glycol alginic acid, chondroitin sulfate, and chitosan.

10 . The method of claim 4 , wherein the pharmaceutical composition is administered in an amount of 1-60 mg per kg of body weight of the subject in need of reducing obesity.

11 . The method of claim 1 , wherein the fat accumulation inhibitory peptide is administered in a health functional food which contains the fat accumulation inhibitory peptide.

12 . The method of claim 11 , wherein the fat accumulation is caused by estrogen deficiency.

Assignees

• Seoul Nat Univ R&Db Foundation
• Nano Intelligent Biomedical Eng Corporation Co Ltd

Inventors

• Chung Chong-Pyoung
• Park Yoon Jeong
• Lee Jue-Yeon
• Suh Jin Sook
• Jo In Ho
• Park Yoon Shin

Classifications

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title

• C07K7/06

  having 5 to 11 amino acids · CPC title

• A23V2002/00

  Food compositions, function of food ingredients or processes for food or foodstuffs · CPC title

• A61K38/16 Primary

  Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)} · CPC title